

HSA SIGNS MEMORANDUM OF UNDERSTANDING WITH THE INDONESIAN FOOD AND DRUG AUTHORITY TO STRENGTHEN REGULATORY COOPERATION ON MEDICINES AND COMPLEMENTARY HEALTH PRODUCTS

Singapore's Health Sciences Authority (HSA) and The Indonesian Food and Drug Authority signed a Memorandum of Understanding (MOU) on 15 January 2026, in Jakarta, Indonesia, marking a significant milestone in cross-border health product cooperation. Both agencies have achieved World Health Organization (WHO) Listed Authority (WLA) status, which recognises that their regulatory systems meet WHO's highest international standards for oversight of medical products, providing a strong foundation for regulatory cooperation. The MOU enables both agencies to share information on regulatory matters pertaining to medicines and complementary health products, to enhance public health protection through shared safety monitoring and quality assurance of these between Singapore and Indonesia.

2 The MOU, signed by the Chief Executive Officer of HSA, Adjunct Professor (Dr) Raymond Chua, and the Chairperson of The Indonesian Food and Drug Authority, Professor (Dr) Taruna Ikrar, covers priority areas, including joint assessment of medicines and complementary health products, clinical trial regulations, emerging areas such as advanced therapy medicinal products and artificial intelligence initiatives in drug regulation, staff training programmes, and post-market safety surveillance of approved products. Refer to the [Annex](#) for photos of the signing ceremony.

3 HSA Chief Executive Officer, Adjunct Professor (Dr) Raymond Chua said: "Collaborative relationships like what we have with our Indonesian counterpart are essential in today's interconnected world, where health challenges require coordinated

responses and shared expertise. Quick information exchange enables timely responses to new health threats, and ensures regulatory decisions are based on the latest safety, quality and efficacy data available. By working together, we can better protect public health in Singapore and Indonesia while building stronger regulatory frameworks that benefit both our jurisdictions, and provide avenues for more efficient regulatory pathways for businesses seeking market access in both countries.”

4 Chairperson of The Indonesian Food and Drug Authority, Professor (Dr) Taruna Ikrar said: “Through this MOU, The Indonesian Food and Drug Authority expects to further deepen collaboration with HSA, particularly as both authorities have attained WHO Listed Authority status. This shared achievement provides a strong foundation to advance joint initiatives, strengthen institutional capacity, and further align regulatory practices with internationally recognised standards, with the ultimate goal of enhancing public health protection across the region.”

**HEALTH SCIENCES AUTHORITY
SINGAPORE
15 JANUARY 2026**

About the Health Sciences Authority (HSA)

The Health Sciences Authority (HSA) applies medical, pharmaceutical and scientific expertise through its three professional groups, Health Products Regulation, Blood Services and Applied Sciences, to protect and advance national health and safety. HSA is a multidisciplinary authority. It serves as the national regulator for health products, ensuring they are wisely regulated to meet standards of safety, quality and efficacy. As the national blood service, it is responsible for providing a safe and adequate blood supply. It also applies specialised scientific, forensic, investigative and analytical capabilities in serving the administration of justice.

For more updates on public health and safety matters, follow us on social media: [LinkedIn](#), [Instagram](#), [X](#) and [YouTube](#).

About HSA's Health Products Regulation Group

The Health Products Regulation Group (HPRG) of HSA ensures that medicines, innovative therapeutics, medical devices and health-related products are wisely regulated and meet appropriate safety, quality and efficacy standards. It contributes to

the development of biomedical sciences in Singapore by administering a robust, scientific and responsive regulatory framework.

ANNEX

PHOTOS AND ADDITIONAL INFORMATION FOR REPORTING

Photo 1: Left to right – Adjunct Professor (Dr) Raymond Chua, Chief Executive Officer, Health Sciences Authority, Singapore and Professor (Dr) Taruna Ikrar, Chairperson, The Indonesian Food and Drug Authority



Photo credit: The Indonesian Food and Drug Authority

Photo 2: Singapore's Health Sciences Authority (HSA) and The Indonesian Food and Drug Authority Memorandum of Understanding Signing



Photo credit: The Indonesian Food and Drug Authority